학술논문
Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial
Document Type
Article
Author
Horne, Andrew W; Vincent, Katy; Hewitt, Catherine A; Middleton, Lee J; Koscielniak, Magda; Szubert, Wojciech; Doust, Ann M; Daniels, Jane P; Abdi, Suraiya; Acharya, Santanu; Al-Inizi, Shamma; Ball, Elizabeth; Baranowski, Andrew; Bhal, Nadia; Bhatia, Kalsang; Bhattacharya, Siladitya; Birch, Judy V.; Carpenter, Tyrone; Chalhoub, Tony; Cheong, Ying C.; Clark, T. Justin; Cregg, Roman; Dada, Tunde D.; Datta, Dib; Faraj, Radwan; Feltham, Max G.; Gupta, Pratima; Hapangama, Dharani; Hardwick, Chris; Hughes, Jon; Khatri, Pinky; Kumar, Geeta; Leighton, Lisa J.; Majumder, Kingshuk; MacFarlane, Gary J.; Mortimer, Alex; Odedra, Smita; Ramsay, Bruce; Raza, Amer; Rea, William; Roy, Somendra; Sajid, Afia; Saraswat, Lucky; Shah, Ahmar; Sivasamy, Jambulingam; Srivastava, Rashmi; Stubbs, Clive; Swaminathan, Ajay; Thampi, Premila; Thanoon, Omar; Thomas, Tony; Tracey, Irene; Underwood, Martyn; Willocks, Clare; Williams, Amanda C de C.; Wood, Simon; Zondervan, Krina
Source
The Lancet; September-October 2020, Vol. 396 Issue: 10255 p909-917, 9p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Chronic pelvic pain affects 2–24% of women worldwide and evidence for medical treatments is scarce. Gabapentin is effective in treating some chronic pain conditions. We aimed to measure the efficacy and safety of gabapentin in women with chronic pelvic pain and no obvious pelvic pathology.